[email protected] Dr. David Armistead joined Oxford Bioscience Partners as an Executive in Residence in 2004. Prior to joining Oxford, he was Vice President and Site Head for the Amgen Cambridge Research Center where he oversaw all aspects of the East Coast research activities for Amgen Inc. In 1997, Dr. Armistead was a co-founder of Kinetix Pharmaceuticals where he held the position of Vice President of Research and Development and Chief Scientific Officer until the acquisition of Kinetix by Amgen in December 2000. His research at Kinetix and Amgen focused on the rational design of selective inhibitors of protein kinases in the fields on inflammation and oncology. Previously, he held the position of Head of Immunosuppressive Research and Development and Senior Scientist-Medicinal Chemistry at Vertex Pharmaceuticals where he focused on the use of structure based drug design for the identification and development of novel therapeutic agents in the areas of immune suppression, cancer, inflammation, neuroprotection and nerve regeneration. Prior to that, Dr. Armistead held the position of Senior Research Chemist in Inflammation and Immunology at Merck Sharp and Dohme Research Laboratories (Merck and Co., Inc.). He left Merck to become a founding member of Vertex in 1989. Dr. Armistead has over 18 years of experience in the pharmaceutical and biotechnology industries. To date, this work has lead to the identification of a number of drug candidates which are currently in human clinical trials in the fields of autoimmune disease, oncology and virology. Dr. Armistead holds a Bachelor of Arts and a Master of Science in Chemistry from Virginia Polytechnic Institute, a Ph.D. in Synthetic Chemistry from the University of South Carolina and was a National Institutes of Health Postdoctoral Fellow at Yale University.